🇺🇸 FDA
Pipeline program

Istaroxime

04-CL-1904

Phase 2 small_molecule active

Quick answer

Istaroxime for Cardiogenic Shock is a Phase 2 program (small_molecule) at WINDTREE THERAPEUTICS INC /DE/ with 2 ClinicalTrials.gov record(s).

Program details

Company
WINDTREE THERAPEUTICS INC /DE/
Indication
Cardiogenic Shock
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials